Video

Dr. Devitt on circulating tumor cells in bladder cancer

Michael Devitt, MD, a hematologist/oncologist and assistant professor at the University of Virginia Medical Center, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

Genomic testing has becoming increasingly critical in bladder cancer, as the FDAapproves novel targeted agents specifically for patients with certain genetic alterations. For example, erdafitinib (Balversa) is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.